drugset
drugset / Trial / NCT01018914

A Study to Compare Safety and Efficacy of Prograf + Myfortic and Advagraf + Myfortic in Liver Transplantation Patients

NCT01018914 ↗

Phase 4 Completed 44 enrolled Astellas Pharma Inc Astellas Pharma Taiwan, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the safety and efficacy of Prograf® with Myfortic® to Advagraf® extended release tacrolimus with Myfortic® in de novo liver transplant recipients.

Timeline

Start
2009-04
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule — Oral
Background mycophenolic acid Small molecule — Oral

Indications

hepatic infarction